Skip to main content
20th International Myeloma Workshop Main banner
Back

    Gareth Morgan, MD, PHD, FRCP, FRCPATH (he/him/his)

    Professor of Medicine, Director of Myeloma Research
    NYU Langone Health Perlmutter Cancer Center, United States

    Gareth J. Morgan. MD, PhD
    Director, Multiple Myeloma Research, Perlmutter Cancer Center, NYU Langone Health
    Professor, Department of Medicine, NYU Grossman School of Medicine

    Dr. Morgan joined Perlmutter Cancer Center in February 2019 as director of multiple myeloma research. He previously served as the director of the Myeloma Institute, deputy director of the Winthrop P. Rockefeller Cancer Institute, & professor of hematology at the University of Arkansas for Medical Sciences, where he directed numerous clinical & translational research studies investigating the treatment, genetics and biology of myeloma. He has been a major contributor to the Myeloma Genome Project, a collaboration to segment & individualize therapy for subgroups of the myeloma.

    Able to speak to many aspects of research & treatment of multiple myeloma including disease prevention & the treatment of patients with high-risk & relapsed refractory disease. Pre-myeloma conditions, including smoldering multiple myeloma (SMM) & monoclonal gammopathy of undetermined significance (MGUS).

    Dr. Morgan’s research focuses on the genetics & biology of multiple myeloma. His laboratory research has identified a number of important genetic prognostic factors, that have been used to developed molecular staging systems for multiple myeloma & smoldering multiple myeloma. He leads clinical trials & studies the molecular mechanisms leading to multiple myeloma with the aim of developing targeted novel treatments & cellular therapies that can improve patient survival. He has developed & served as principal investigator on a number of large Phase III clinical studies, that have substantially changed the clinical approach to the treatment of multiple myeloma & were among the largest myeloma studies ever conducted. The results of these studies set the standard for the management of bone disease, introduced & expanded the use of autologous transplantation, & led to the uptake of maintenance therapies using immunomodulatory drugs & proteasome inhibitors for multiple myeloma.

    Presentation(s):